Cover Image
市場調查報告書

中國的Valsartan市場調查

Investigation Report on China Valsartan Market, 2009-2018

出版商 China Research and Intelligence 商品編碼 296112
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Valsartan市場調查 Investigation Report on China Valsartan Market, 2009-2018
出版日期: 2014年02月14日 內容資訊: 英文 40 Pages
簡介

Valsartan(Angiotan或Diovan)是一種血管收縮素Ⅱ受體拮抗劑(一般稱作ARB或血管收縮素II受體阻斷劑),尤其是其具有與第1型血管收縮素受體的高親和性。Valsartan在1996年通過FDA的核可,1998年在中國透過Novartis登記為「Daiwen」這個商標名稱。自Valsartan以後,Novartis便在開發Valsartan複合調劑。1997年十月,valsartan/hydrochlorothiazide以「CoDiovan」這個商標名稱通過FDA的核可,同時也推出了新開發的amlodipine/valsartan (Exforge) 。Valsartan的最終產品市場由Novartis佔有每年85%以上銷售額的佔有率。預測中國高血壓患者將突破2億人。

本報告提供中國的Valsartan市場相關分析,提供主要廠商的市場佔有率,中國的醫院市場上價格變化·銷售額,再加上主要企業,及市場展望等,為您概述為以下內容。

第1章 Valsartan相關的概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的Valsartan的市場概要

  • 專利情形
  • 主要製造商
  • 市場規模

第3章 中國的Valsartan的銷售額調查

  • 整體銷售額
  • 銷售額:各地區

第4章 中國的主要Valsartan製造商的市場佔有率調查

  • 市場佔有率:各銷售額
  • 市場佔有率:不同銷售額

第5章 Valsartan的市場規模調查:中國的投藥形態別

  • 市場佔有率:銷售額·投藥形態別
  • 市場佔有率:銷售額·投藥形態別

第6章 中國的醫院市場上Valsartan的標準價格

  • Tianda Group
  • Livzon Pharmaceutical Factory of Livzon Group
  • Beijing Novartis Pharma Co., Ltd.
  • Beijing Saike Pharmaceutical Co., Ltd.
  • Guilin Winsun Pharmaceutical Co., Ltd.
  • Changzhou Siyao Pharmaceutical Co., Ltd.
  • Hainan Bright Future Pharmaceutical Co.,Ltd.
  • Hainan Hualon Pharmaceutical Co., Ltd.

第7章 中國的主要Valsartan製造商分析

  • Beijing Novartis
  • Beijing Saike
  • Changzhou Siyao
  • Hainan Hualon
  • Lunan Better

第8章 中國的Valsartan市場展望

  • 市場規模預測
  • 競爭格局預測

主要表(圖表)

目錄
Product Code: 1402107

Valsartan (Angiotan or Diovan) is an angiotensin II receptor antagonist (more commonly called an ARB, or angiotensin receptor blocker), with particularly high affinity for the type I (AT1) angiotensin receptor. In December 1996, Valsartan was approved by FDA. In the US, UK and Australia, valsartan is marketed by Novartis under the trade name Diovan. In 1998, Valsartan was registered by Novartis in China with "Daiwen" as its brand name. After Valsartan, Novartis developed Valsartan compound preparation. In October 1997, valsartan/hydrochlorothiazide was approved by FDA with "CoDiovan" as its brand name; New developed amlodipine/valsartan (Exforge) was also approved to the market.

There are many enterprises producing APIs and finished products of Valsartan. The market share of finished products is mainly occupied by Novartis, which is above 85% by sales value every year.

In China, the number of hypertensive patients has exceeded 200 million so the market prospect of Valsartan is bright.

Through this report, the readers can acquire the following information:

  • Market Share of Major Valsartan Manufacturers in Sampling Hospitals in China
  • Sales price of valsartan in hospital market in China
  • Major valsartan enterprises in China
  • Market share of valsartan by dosage form in hospital market in China
  • Prospect of China valsartan market

The Following Enterprises and People Are Recommended to Purchase This Report:

  • Valsartan API and finished product manufacturers
  • Medical Institutions
  • Investors /research agencies focusing on valsartan market

Table of Contents

1. Relevant Concepts of Valsartan

  • 1.1. Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Valsartan in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Valsartan in China, 2009-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Valsartan Manufacturers in China, 2009-2013

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Valsartan by Dosage Form in China, 2009-2013

  • 5.1. Market Share by Sales Value and Dosage Form
  • 5.2. Market Share by Sales Volume and Dosage Form

6. Reference Price of Valsartan in Hospital Market in China, 2013

  • 6.1. Tianda Group
  • 6.2. Livzon Pharmaceutical Factory of Livzon Group
  • 6.3. Beijing Novartis Pharma Co., Ltd.
  • 6.4. Beijing Saike Pharmaceutical Co., Ltd.
  • 6.5. Guilin Winsun Pharmaceutical Co., Ltd.
  • 6.6. Changzhou Siyao Pharmaceutical Co., Ltd.
  • 6.7. Hainan Bright Future Pharmaceutical Co.,Ltd.
  • 6.8. Hainan Hualon Pharmaceutical Co., Ltd.

7. Anallysis on Major Valsartan Manufacturers in China, 2009-2013

  • 7.1. Beijing Novartis
  • 7.2. Beijing Saike
  • 7.3. Changzhou Siyao
  • 7.4. Hainan Hualon
  • 7.5. Lunan Better

8. Prospect of China Valsartan Market, 2014-2018

  • 8.1. Forecast on Market Size
  • 8.2. Forecast on Competition Pattern

Selected Charts

  • Chart Valsartan Products Approved to Market in China, 2014
  • Chart Forecast on Market Size of Hospital-use Valsartan in China, 2014-2018
  • Chart Sales Value of Valsartan in Global Market, 2009-2013
  • Chart Sales Value of Valsartan in Hospital Market in China, 2009-2013
  • Chart Sales Value of Valsartan by Region in China, 2009-2013
  • Chart Market Share of Valsartan Enterprises by Sales Value in China, 2009-2013
  • Chart Hospital Price of Valsartan Produced by Tianda Group
  • Chart Hospital Price of Valsartan Produced by Beijing Novartis
Back to Top